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Abstract
In the heart, ischemia=reperfusion damage occurs mainly during the first minutes of reperfusion. Recently, it has
been shown that the heart can be protected against the extension of ischemia=reperfusion injury if brief coronary
occlusions are performed just at the beginning of the reperfusion. This procedure has been called post-
conditioning (PostC). It can also be elicited by pharmacological intervention, that is, pharmacological PostC. In
particular, PostC limits infarct size, apoptosis, endothelial dysfunction, neutrophil adherence, and arrhythmias.
Similar to preconditioning, PostC may trigger signaling pathways, including reperfusion injury salvage kinase
and survivor activating factor enhancement pathways. PostC-induced protection also involves intracellular
acidosis and early redox-sensitive mechanisms. However, controversies exist on the nature of receptors and
main pathway(s) involved in PostC. Protective pathways activated by PostC appear to converge on mito-
chondria and, in particular, on mitochondrial permeability transition pores. Preliminary clinical data indicate
that drugs targeting mitochondrial permeability transition pore or reperfusion injury salvage kinases may confer
benefits to patients with acute myocardial infarction above that provided by myocardial reperfusion alone.
Future studies must define the principal protective cascades, the interdependence of the signaling pathways, and
the optimal pharmacological target and agent(s) for protection. These studies must also consider the possible
confounding effects of comorbidities and their drug treatments. Antioxid. Redox Signal. 14, 777–779.
Introduction
Myocardial infarction is the major cause of mortalityin industrialized countries. Therefore, protecting the
heart from ischemia- and reperfusion-induced injury repre-
sents the greatest challenge of modern cardiology.
It is now clear that the mammalian heart can partially or
totally recover its pump function only if coronary flow is
promptly restored in the ischemic area. In fact, reperfusion is
the crucial treatment to reduce all manifestations of postis-
chemic injury. On the contrary, when it is not possible to start
an early reperfusion, the progression of ischemic-induced al-
terations causes irreversible damage that leads inexorably to
contractile dysfunction and cell death. Although early re-
perfusion is the only way to salvage an ischemic cell, during
the crucial early moments of reperfusion, significant irre-
versible cell damage is initiated, which is referred to as re-
perfusion injury. These include cell death by necrosis and
apoptosis, contractile dysfunction, arrhythmias, microvascu-
lar injury or ‘‘no-reflow,’’ and inflammatory responses (7, 11).
Therefore, both ischemia and reperfusion contribute to organ
injury. However, different animal species can tolerate ex-
tremely different levels of oxygenation. Cardioprotective in-
terventions may render the mammalian heart more resistant
to ischemia=reperfusion challenges. An important issue of
cardioprotection research is to understand the mechanisms
underlying heart vulnerability and resistance against ische-
mia. To address this issue, the present forum presents an el-
egant review on the tolerance of vertebrate hearts to hypoxia
and anoxia in an evolutionary and comparative perspective
(10). In this respect, it is particularly intriguing that cardio-
protective interventions against reperfusion injury can be
performed either before infracting=index ischemia (pre-
conditioning) or in the early moments of reperfusion, which
follows ischemia [postconditioning (PostC)].
PostC Cardioprotection
Cardioprotective interventions can be pharmacological or
mechanical (brief periods of ischemia=reperfusion or gen-
tle=gradual reperfusion) in nature. In fact, paradoxically,
survival mechanisms in the heart can be triggered by short,
nonlethal periods of ischemia and reperfusion, applied either
before (ischemic preconditioning) or immediately after (is-
chemic or mechanical PostC) an infarcting=index ischemia.
The present forum analyzes the accumulating amount of ev-
idence that lethal reperfusion injury may be reduced by is-
chemic or pharmacological PostC in animals (1–11) and in
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small-sized clinical trials (6). Vinten-Johansen and collabora-
tors discuss the protective effect of PostC against infarct size,
arrhythmias, stunning, and vascular dysfunction (11). PostC
activates signaling pathways, which involve triggers, medi-
ators, and end-effector(s): the contribution of each of these
players may vary depending on the experimental model (cell
type, species, in vivo, ex vivo, and in vitro) and the PostC
stimulus used (Fig. 1). The triggers, with particular attention
paid to adenosine and its receptors, are considered in the re-
view by Cohen and Downey (2). The exact nature of receptors
involved in triggering protection remains a matter of contro-
versy (2, 7). The mediators, mostly protein kinases, are clearly
discussed by Hausenloy et al. (4). In this review (4), the re-
perfusion injury salvage kinase pathway and the more re-
cently described survivor activating factor enhancement
pathways, two apparently distinct signaling pathways, are
considered. In these two reviews (2, 4), the authors bring up-
to-date useful concepts on mechanisms in a constantly
changing field. Controversy on the role of reperfusion injury
salvage kinase is also discussed (4, 7). Inserte et al. (5) elegantly
discuss interactions between intracellular acidosis and en-
dogenous protection signaling. Low intracellular pH, in fact,
inhibits many mechanisms involved in reperfusion injury,
including opening of mitochondrial permeability transition
pore (mPTP) and activation of calpains. Accumulating evi-
dences show the importance of acidotic environment in early
reperfusion for cardioprotection. The protective molecular
pathways are incompletely understood but it is very likely
that they converge on mitochondria, where suppression of
mPTP opening during early reperfusion is considered the key
event preventing cell death at reperfusion (Fig. 1). The end
effectors within mitochondria and, in particular, the regula-
tion of mPTP and its implication for cell pathology are dis-
cussed by Di Lisa et al. (3). The review by Boengler et al. (1)
clearly discusses how modifications of mitochondrial func-
tion and mPTP opening contribute to cardiac patho-
physiology, specifically during reperfusion. The role of
mitochondria in loss of PostC protection in diseased or aged
myocardium is also discussed (1). The importance of mito-
chondria is outlined by all the authors of the forum, as many
components of these organelles are involved in cardiopro-
tective mechanisms. Different aspects of the role of these or-
ganelles are analyzed in more detail by Boengler et al. (1), Di
Lisa et al. (3), and Pagliaro et al. (7). These insights have been
already translated to the treatment of patients with reperfused
acute myocardial infarction (6). Both PostCwith ischemia and
with drugs have been used in humans, and useful clinical
information is given in the review by Ovize and coworkers
(6). Intriguingly, there appear to be redundant cardioprotec-
tive pathways; these pathways, their interactions, and their
influences by redox environment are discussed by Pagliaro
et al. (7). In particular, redox signaling is suggested to play a
role in both preconditioning and PostC during the initial part
of reperfusion that follows the infarcting ischemia (7).
The extent of protection by ischemic PostC is influenced by
many variables including the duration of index ischemia, the
PostC protocol, the species, gender, and even interindividual
variations. The influence of confounding factors (Fig. 1), in-
cluding the classical coronary artery disease risk factors, drug
treatments, gender, and age, on PostC efficacy is discussed by
Vinten-Johansen et al. (11). The original article by Przyklenk
et al. (8) shows how diabetic conditions and therapies may
influence PostC efficacy. Some features of pharmacological
PostC are also considered in the review of Losano and co-
workers (9), where the unique aspects of the protective effects
of Apelin are analyzed.
Conclusions and Open Questions
Methods to protect the heart during reperfusion are of great
clinical interest. It is now clear that protective interventions
must be applied early on, and the first seconds to minutes
have the most significant impact on ‘‘acute’’ reperfusion in-
jury, as shown in many experimental studies reported in the
reviews of the present forum. There is indeed the necessity to
define the optimal protective protocol for a given duration of
index ischemia and for disparate clinical manifestations. It is
also of utmost importance to define the principal protective
cascades, the interdependence of the signaling pathways, and
the optimal pharmacological target and agent (classical or
innovative) for protection. This should be done in preclinical
and clinical studies, which must also consider the possible
comorbidities and their drug treatments. In fact, under-
standing the modifications of the protective pathways in the
presence of comorbidities and their therapies is also of para-
mount importance. Finally, clinical trials, including large
multicenter studies, to determine the impact of ischemic and
pharmacological PostC on patient outcomes are mandatory.
FIG. 1. Protective cascade and signaling pathways, which
involve triggers and mediators converging on mitochon-
dria, where end-effector(s) reside. Controversies and con-
founding factors are highlighted. Future studies must deal
with these controversies and solve the conundrum of con-
founding factors in the setting of aging, diabetes, hyperten-
sion, and other diseases. The double-headed arrow indicates the
cross-talk between mediators and end-effectors. In particu-
lar, reactive oxygen species generated by mitochondria may
influence other cytosolic components (e.g., kinases, phos-
phatases, and other enzymes), which in turn may influence
mitochondrial function. The numbers in parentheses are
references that address in more detail the various points of
the protective cascade and discuss the controversy present in
the literature. Adenosine receptors subtypes: A1, A2a, A2b,
A3; bradykinin receptors subtypes: B1, B2; opiods receptors
subtypes: m, d, k. mKATP, mitochondrial Kþ ATP channels;
mPTP, mitochondrial permeability transition pore; pHi, in-
tracellular pH; RISK, reperfusion injury salvage kinase;
SAFE, survivor activating factor enhancement.
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These studies must include an appropriate number of patients
to allow for accurate statistical stratification into subsets ac-
cording to individual comorbidities, multiple comorbidities,
andmedications used to treat acute or chronic coronary artery
disease.
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mKATP¼mitochondrial Kþ ATP channels
mPTP¼mitochondrial permeability transition
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RISK¼ reperfusion injury salvage kinase
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